Brief: Chinook Therapeutics Reports Initiation Of Phase 1 Trial Of CHK-336
12/04/2022 13:16
April 12 (Reuters) - Chinook Therapeutics Inc KDNY.O :
* CHINOOK THERAPEUTICS ANNOUNCES INITIATION OF PHASE 1
HEALTHY
VOLUNTEER TRIAL OF CHK-336, A FIRST-IN-CLASS LDHA INHIBITOR TO
TREAT HYPEROXALURIAS
Source text for Eikon: ID:nGNX77z5SG
Further company coverage: KDNY.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Chinook Therapeutics
See all newsBrief: Novartis Completes Acquisition Of Chinook Therapeutics
Chinook Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Chinook Therapeutics Inc expected to post a loss of 81 cents a share - Earnings Preview
Brief: Chinook Therapeutics Announces First Patient Enrolled In Phase 3 Of Zigakibart
Brief: Muddy Waters- Remains Short On Chinook Therapeutics Inc